Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Intravenously Administered LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Intravenously Administered LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LP-284 (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Lantern Pharma

Most Recent Events

  • 08 Aug 2024 According to a Lantern Pharma media release, company announced the dosing of the third cohort patient in the Phase 1 clinical trial.
  • 09 May 2024 According to a Lantern Pharma media release, the company expects to open additional sites in the US throughout the second quarter with the potential to advance to Phase 1b/2 by the close of 2024.
  • 10 Apr 2024 Trial design, presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top